124 related articles for article (PubMed ID: 38897040)
41. Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential.
Furuta S; Akagawa N; Kamada E; Hiyama A; Kawabata Y; Kowata N; Inaba A; Matthews A; Hall M; Kurimoto T
Br J Clin Pharmacol; 2002 Sep; 54(3):295-303. PubMed ID: 12236850
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of soluble epoxide hydrolase confers cardioprotection and prevents cardiac cytochrome P450 induction by benzo(a)pyrene.
Aboutabl ME; Zordoky BN; Hammock BD; El-Kadi AO
J Cardiovasc Pharmacol; 2011 Mar; 57(3):273-81. PubMed ID: 21383588
[TBL] [Abstract][Full Text] [Related]
43. Development of Dual Inhibitors of Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase with Tetrazole Core.
Mehrandish S; Rezaee E; Sedaghat A; Heidarli E; Naderi N; Tabatabai SA
Med Chem; 2023; 19(10):1037-1048. PubMed ID: 37464836
[TBL] [Abstract][Full Text] [Related]
44. Benzoxazolone-5-Urea Derivatives as Human Soluble Epoxide Hydrolase (sEH) Inhibitors.
Gur Maz T; Koc B; Jordan PM; İbiş K; Çalışkan B; Werz O; Banoglu E
ACS Omega; 2023 Jan; 8(2):2445-2454. PubMed ID: 36687110
[TBL] [Abstract][Full Text] [Related]
45. Regulation of cardiovascular biology by microsomal epoxide hydrolase.
Edin ML; Zeldin DC
Toxicol Res; 2021 Jul; 37(3):285-292. PubMed ID: 34295793
[TBL] [Abstract][Full Text] [Related]
46. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of cytochrome P450 inhibition assays using human liver microsomes by a cassette analysis /LC-MS/MS.
Zambon S; Fontana S; Kajbaf M
Drug Metab Lett; 2010 Aug; 4(3):120-8. PubMed ID: 20642444
[TBL] [Abstract][Full Text] [Related]
48. Adamantyl thioureas as soluble epoxide hydrolase inhibitors.
Burmistrov V; Morisseau C; Pitushkin D; Karlov D; Fayzullin RR; Butov GM; Hammock BD
Bioorg Med Chem Lett; 2018 Jul; 28(13):2302-2313. PubMed ID: 29803731
[TBL] [Abstract][Full Text] [Related]
49. Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
Kodani SD; Bhakta S; Hwang SH; Pakhomova S; Newcomer ME; Morisseau C; Hammock BD
Bioorg Med Chem Lett; 2018 Feb; 28(4):762-768. PubMed ID: 29366648
[TBL] [Abstract][Full Text] [Related]
50. Protostane-type triterpenoids as natural soluble epoxide hydrolase inhibitors: Inhibition potentials and molecular dynamics.
Sun CP; Zhang J; Zhao WY; Yi J; Yan JK; Wang YL; Morisseau C; Liu ZB; Hammock BD; Ma XC
Bioorg Chem; 2020 Mar; 96():103637. PubMed ID: 32032849
[TBL] [Abstract][Full Text] [Related]
51. Oxetane Substrates of Human Microsomal Epoxide Hydrolase.
Toselli F; Fredenwall M; Svensson P; Li XQ; Johansson A; Weidolf L; Hayes MA
Drug Metab Dispos; 2017 Aug; 45(8):966-973. PubMed ID: 28600384
[TBL] [Abstract][Full Text] [Related]
52. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs.
Lieu C; Shi J; Donat F; Van Horn R; Brian W; Newton J; Delbressine L; Vos R
Clin Pharmacokinet; 2002; 41 Suppl 2():19-26. PubMed ID: 12383041
[TBL] [Abstract][Full Text] [Related]
53. Discovery of novel drug candidates for inhibition of soluble epoxide hydrolase of arachidonic acid cascade pathway implicated in atherosclerosis.
Gurung AB; Mayengbam B; Bhattacharjee A
Comput Biol Chem; 2018 Jun; 74():1-11. PubMed ID: 29522918
[TBL] [Abstract][Full Text] [Related]
54. Endogenous role of microsomal epoxide hydrolase. Ontogenesis, induction inhibition, tissue distribution, immunological behaviour and purification of microsomal epoxide hydrolase with 16 alpha, 17 alpha-epoxyandrostene-3-one as substrate.
Vogel-Bindel U; Bentley P; Oesch F
Eur J Biochem; 1982 Aug; 126(2):425-31. PubMed ID: 7128597
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
Katoh M; Nakajima M; Shimada N; Yamazaki H; Yokoi T
Eur J Clin Pharmacol; 2000; 55(11-12):843-52. PubMed ID: 10805063
[TBL] [Abstract][Full Text] [Related]
56. Soluble epoxide hydrolase: a novel target for the treatment of hypertension.
Fang X
Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):67-72. PubMed ID: 18221075
[TBL] [Abstract][Full Text] [Related]
57. Effects of eleven isothiocyanates on P450 2A6- and 2A13-catalyzed coumarin 7-hydroxylation.
von Weymarn LB; Chun JA; Knudsen GA; Hollenberg PF
Chem Res Toxicol; 2007 Sep; 20(9):1252-9. PubMed ID: 17672516
[TBL] [Abstract][Full Text] [Related]
58. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole.
Ueng YF; Hsieh CH; Don MJ
Food Chem Toxicol; 2005 May; 43(5):707-12. PubMed ID: 15778010
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
Mössner LD; Schmitz A; Theurillat R; Thormann W; Mevissen M
Am J Vet Res; 2011 Nov; 72(11):1505-13. PubMed ID: 22023129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
